Gulf International Bank UK Ltd Invests $758,000 in Natera, Inc. $NTRA

Key Points

• Gulf International Bank UK Ltd has acquired a new stake in Natera, Inc., purchasing 5,364 shares valued at approximately $758,000.
• Institutional investors control a substantial 99.90% of Natera's stock, indicating strong institutional interest in the company.
• Natera's stock received a mix of ratings from analysts, with targets ranging from $193.19 to $255.00, reflecting varying levels of confidence in its future performance.

Gulf International Bank UK Ltd acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,364 shares of the medical research company's stock, valued at approximately $758,000.

Other large investors have also added to or reduced their stakes in the company. HighPoint Advisor Group LLC increased its position in Natera by 30.8% in the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after acquiring an additional 468 shares during the period. Amalgamated Bank grew its stake in shares of Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after purchasing an additional 740 shares during the last quarter. GAMMA Investing LLC increased its holdings in Natera by 32.3% in the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after purchasing an additional 207 shares during the period. Teza Capital Management LLC bought a new position in Natera during the 4th quarter worth $221,000. Finally, Asset Management One Co. Ltd. bought a new position in Natera during the 1st quarter worth $6,753,000. Institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 6,111 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.10, for a total transaction of $960,038.10. Following the sale, the chief executive officer owned 179,071 shares of the company's stock, valued at $28,132,054.10. This trade represents a 3.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,792 shares of company stock valued at $9,227,972 in the last 90 days. Corporate insiders own 5.63% of the company's stock.

Natera Price Performance

Shares of Natera stock traded up $0.52 during trading on Wednesday, reaching $160.64. 1,349,212 shares of the company traded hands, compared to its average volume of 1,522,684. The firm has a market capitalization of $22.05 billion, a PE ratio of -84.10 and a beta of 1.76. Natera, Inc. has a 1-year low of $110.57 and a 1-year high of $183.00. The company has a 50 day moving average price of $155.02 and a 200-day moving average price of $154.43.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period last year, the firm posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on NTRA shares. Barclays reissued an "overweight" rating and issued a $210.00 price target (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Piper Sandler restated an "overweight" rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Stephens restated an "overweight" rating and issued a $183.00 price target on shares of Natera in a research report on Friday, August 15th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $193.19.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.